報價延遲最少15分鐘:2024/12/23 22:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.12 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.12/-0.91
|
|
企業價值
2.09B
|
| 資產負債 |
|
每股賬面淨值
0.93
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
113.31M
|
|
每股收益
0.24
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease. |